CG Oncology (CGON) is moving higher as the market continues to trade the company around an approaching catalyst window in the first half of 2026, when the company expects to report topline data from its Phase 3 PIVOT-006 trial evaluating cretostimogene as an adjuvant therapy in intermediate-risk non-muscle invasive bladder cancer. With the next major readout nearing, biotech traders often bid up shares on “catalyst anticipation,” especially when the program is central to the company’s thesis. (globenewswire.com)

Sell-side sentiment has also been supportive following a series of price-target increases tied to the upcoming PIVOT-006 disclosure and broader optimism around cretostimogene’s development path. One notable move earlier this year was a Truist Securities price-target increase to $75 while maintaining a Buy rating, citing the approaching first-half 2026 topline results. (investing.com)

The near-term focus remains the timing and quality of the PIVOT-006 topline data and additional first-half 2026 updates the company has flagged, including initial results from a Phase 2 combination cohort (CORE-008 Cohort CX) pairing cretostimogene with gemcitabine in high-risk NMIBC. Beyond clinical data, investors are also watching for any incremental corporate or financial updates as the company approaches its next expected earnings window in early May 2026. (globenewswire.com)

Because CG Oncology is still in a development-heavy stage, the stock can be especially sensitive to shifts in perceived probability of success for its lead program and any changes to trial timelines. A key takeaway from prior updates is that the company has framed PIVOT-006 topline data as a first-half 2026 event, which can concentrate volatility as that window progresses and traders react to new information. (investing.com)